Genome-wide network of antibiotic susceptibility in Pseudomonas aeruginosa
- Journal
- The Journal of antimicrobial chemotherapy (Q1)
- Published
- 4 August 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Océane Goncalves, Jean-Philippe Côté
- PMID
- 42554208
- DOI
- 10.1093/jac/dkag272
Why clinicians should know about it
- Picked for Microbiology (medical) (paper of the day, 6 August 2026): Genome‑wide network of antibiotic susceptibility in P. aeruginosa
Abstract
BACKGROUND AND OBJECTIVE: Pseudomonas aeruginosa is a ubiquitous Gram-negative pathogen notorious for causing infections with high mortality rates. Its large genome supports extensive metabolic diversity and promotes its adaptation to diverse environments. The survival and persistence of P. aeruginosa in clinical settings is further facilitated by a vast arsenal of strategies that contribute to its tolerance or resistance to antibiotics. Here, we aimed to systematically identify the genetic determinants that affect its susceptibility to antibiotics. METHODS: The ordered PA14 transposon mutant library was grown in the presence of sub-MIC concentrations of a panel of antibiotics of various classes, and the growth of each mutant was quantified to generate susceptibility scores. RESULTS: We observed a dense network of genes affecting antibiotic susceptibility in P. aeruginosa, where a large portion of genes modulated susceptibility to various classes of antibiotics. Not surprisingly, efflux and outer membrane permeability were key contributors, but we also identified genes that are not typically associated with antibiotic susceptibility. CONCLUSIONS: The data provide a genome-wide view of the antibiotic susceptibility network in P. aeruginosa. Overall, our approach deepens our understanding of antibiotic susceptibility and opens new avenues for developing strategies against multidrug-resistant P. aeruginosa.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.